Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type α1(1) collagen gene promoter in normal and fibrotic rats

Kun Cheng, Zhaoyang Ye, Ramareddy Guntaka, Ram I. Mahato

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Fibrosis is characterized by excessive production of extracellular matrix (ECM) components, predominantly type 1 collagen. Earlier we developed an antigene approach, using a type α1(I) promoter specific TFO to inhibit collagen gene expression. In this report, biodistribution and hepatic cellular and subcellular localization of the 25-mer antiparallel phosphorothioate triplex-forming oligonucleotide (APS TFO) were determined after intravenous injection into rats. TFOs distributed to all the major organs, with higher uptake in the liver, kidney, and spleen. The plasma concentration versus time profile of the 33 P-TFO was biphasic, with 4.36 min as t 1/2α of distribution and 34.6 min as t 1/2β of elimination. TFO concentrations in the liver increased nonlinearly with increase in its dose from 0.2 to 50 mg/kg, but decreased when injected into fibrotic rats. Competition studies with polyinosinic acid (polyl) and dextran sulfate suggested the involvement of scavenger receptors in the hepatic uptake of the TFO. Intrahepatic cellular distribution by Kupffer, endothelial, and hepatic stellate cells (HSCs) accounted for almost 70% of the liver uptake of 33 P-TFO, while only 30% was associated with hepatocytes. The level of liver nuclei-associated TFO was much lower relative to that found in the cytoplasm at 2 and 4 h postinjection, TFO, however, inhibited collagen expression as evidenced by Sirius red staining of the liver section of fibrotic rats. In conclusion, systemic delivery of the TFO against type α1(I) collagen gene promoter may be used for the treatment of liver fibrosis.

Original languageEnglish (US)
Pages (from-to)206-217
Number of pages12
JournalMolecular Pharmaceutics
Volume2
Issue number3
DOIs
StatePublished - May 1 2005

Fingerprint

Oligonucleotides
Collagen
Liver
Genes
Collagen Type I
Poly I
Scavenger Receptors
Hepatic Stellate Cells
Dextran Sulfate
Intravenous Injections
Liver Cirrhosis
Extracellular Matrix
Hepatocytes
Cytoplasm
Fibrosis
Spleen
Staining and Labeling
Kidney
Gene Expression

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmaceutical Science
  • Drug Discovery

Cite this

Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type α1(1) collagen gene promoter in normal and fibrotic rats. / Cheng, Kun; Ye, Zhaoyang; Guntaka, Ramareddy; Mahato, Ram I.

In: Molecular Pharmaceutics, Vol. 2, No. 3, 01.05.2005, p. 206-217.

Research output: Contribution to journalArticle

@article{cce83804a1044a80b59e0c0f236c6be7,
title = "Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type α1(1) collagen gene promoter in normal and fibrotic rats",
abstract = "Fibrosis is characterized by excessive production of extracellular matrix (ECM) components, predominantly type 1 collagen. Earlier we developed an antigene approach, using a type α1(I) promoter specific TFO to inhibit collagen gene expression. In this report, biodistribution and hepatic cellular and subcellular localization of the 25-mer antiparallel phosphorothioate triplex-forming oligonucleotide (APS TFO) were determined after intravenous injection into rats. TFOs distributed to all the major organs, with higher uptake in the liver, kidney, and spleen. The plasma concentration versus time profile of the 33 P-TFO was biphasic, with 4.36 min as t 1/2α of distribution and 34.6 min as t 1/2β of elimination. TFO concentrations in the liver increased nonlinearly with increase in its dose from 0.2 to 50 mg/kg, but decreased when injected into fibrotic rats. Competition studies with polyinosinic acid (polyl) and dextran sulfate suggested the involvement of scavenger receptors in the hepatic uptake of the TFO. Intrahepatic cellular distribution by Kupffer, endothelial, and hepatic stellate cells (HSCs) accounted for almost 70{\%} of the liver uptake of 33 P-TFO, while only 30{\%} was associated with hepatocytes. The level of liver nuclei-associated TFO was much lower relative to that found in the cytoplasm at 2 and 4 h postinjection, TFO, however, inhibited collagen expression as evidenced by Sirius red staining of the liver section of fibrotic rats. In conclusion, systemic delivery of the TFO against type α1(I) collagen gene promoter may be used for the treatment of liver fibrosis.",
author = "Kun Cheng and Zhaoyang Ye and Ramareddy Guntaka and Mahato, {Ram I.}",
year = "2005",
month = "5",
day = "1",
doi = "10.1021/mp050012x",
language = "English (US)",
volume = "2",
pages = "206--217",
journal = "Molecular Pharmaceutics",
issn = "1543-8384",
publisher = "American Chemical Society",
number = "3",

}

TY - JOUR

T1 - Biodistribution and hepatic uptake of triplex-forming oligonucleotides against type α1(1) collagen gene promoter in normal and fibrotic rats

AU - Cheng, Kun

AU - Ye, Zhaoyang

AU - Guntaka, Ramareddy

AU - Mahato, Ram I.

PY - 2005/5/1

Y1 - 2005/5/1

N2 - Fibrosis is characterized by excessive production of extracellular matrix (ECM) components, predominantly type 1 collagen. Earlier we developed an antigene approach, using a type α1(I) promoter specific TFO to inhibit collagen gene expression. In this report, biodistribution and hepatic cellular and subcellular localization of the 25-mer antiparallel phosphorothioate triplex-forming oligonucleotide (APS TFO) were determined after intravenous injection into rats. TFOs distributed to all the major organs, with higher uptake in the liver, kidney, and spleen. The plasma concentration versus time profile of the 33 P-TFO was biphasic, with 4.36 min as t 1/2α of distribution and 34.6 min as t 1/2β of elimination. TFO concentrations in the liver increased nonlinearly with increase in its dose from 0.2 to 50 mg/kg, but decreased when injected into fibrotic rats. Competition studies with polyinosinic acid (polyl) and dextran sulfate suggested the involvement of scavenger receptors in the hepatic uptake of the TFO. Intrahepatic cellular distribution by Kupffer, endothelial, and hepatic stellate cells (HSCs) accounted for almost 70% of the liver uptake of 33 P-TFO, while only 30% was associated with hepatocytes. The level of liver nuclei-associated TFO was much lower relative to that found in the cytoplasm at 2 and 4 h postinjection, TFO, however, inhibited collagen expression as evidenced by Sirius red staining of the liver section of fibrotic rats. In conclusion, systemic delivery of the TFO against type α1(I) collagen gene promoter may be used for the treatment of liver fibrosis.

AB - Fibrosis is characterized by excessive production of extracellular matrix (ECM) components, predominantly type 1 collagen. Earlier we developed an antigene approach, using a type α1(I) promoter specific TFO to inhibit collagen gene expression. In this report, biodistribution and hepatic cellular and subcellular localization of the 25-mer antiparallel phosphorothioate triplex-forming oligonucleotide (APS TFO) were determined after intravenous injection into rats. TFOs distributed to all the major organs, with higher uptake in the liver, kidney, and spleen. The plasma concentration versus time profile of the 33 P-TFO was biphasic, with 4.36 min as t 1/2α of distribution and 34.6 min as t 1/2β of elimination. TFO concentrations in the liver increased nonlinearly with increase in its dose from 0.2 to 50 mg/kg, but decreased when injected into fibrotic rats. Competition studies with polyinosinic acid (polyl) and dextran sulfate suggested the involvement of scavenger receptors in the hepatic uptake of the TFO. Intrahepatic cellular distribution by Kupffer, endothelial, and hepatic stellate cells (HSCs) accounted for almost 70% of the liver uptake of 33 P-TFO, while only 30% was associated with hepatocytes. The level of liver nuclei-associated TFO was much lower relative to that found in the cytoplasm at 2 and 4 h postinjection, TFO, however, inhibited collagen expression as evidenced by Sirius red staining of the liver section of fibrotic rats. In conclusion, systemic delivery of the TFO against type α1(I) collagen gene promoter may be used for the treatment of liver fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=21444439431&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21444439431&partnerID=8YFLogxK

U2 - 10.1021/mp050012x

DO - 10.1021/mp050012x

M3 - Article

VL - 2

SP - 206

EP - 217

JO - Molecular Pharmaceutics

JF - Molecular Pharmaceutics

SN - 1543-8384

IS - 3

ER -